PD-1 Clinical Trials

27 clinical trials for PD-1 across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors — RECRUITING
• Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer — RECRUITING · PHASE1
• A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications. — RECRUITING
• Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients — RECRUITING
• HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC — RECRUITING
• Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004) — RECRUITING · PHASE2
• 4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC — RECRUITING · PHASE2
• PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy — RECRUITING · PHASE3
• Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma — RECRUITING · PHASE3
• Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma （HNC-SYSU-005） — ACTIVE_NOT_RECRUITING · PHASE2
• Biomarker Analysis of Tislelizumab Combined With Chemotherapy for Perioperative Treatment of G/GEJ Adenocarcinoma — COMPLETED
• A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma — NOT_YET_RECRUITING · PHASE2
• A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC) — NOT_YET_RECRUITING · PHASE2
• PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006) — NOT_YET_RECRUITING · PHASE2
• A Prospective Study: the Impact of Sleep Disturbances on Immunotherapy in Patients With Lung Cancer — NOT_YET_RECRUITING
• Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer — NOT_YET_RECRUITING · PHASE2
• LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer — OTHER · PHASE2
• Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction — OTHER · PHASE2
• Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer — OTHER · PHASE1
• RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC — OTHER · PHASE2
• A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — OTHER · PHASE2
• PD-1 Antibody for Reactive EBV After BMT — OTHER · PHASE1
• A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study — OTHER · PHASE2
• PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC — OTHER · PHASE2
• Genetic Mutation in Epithelial Ovarian Cancer — OTHER
• Genetic Mutation in Recurrent Cervical Cancer — OTHER
• Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ — OTHER · PHASE1

Refine this search